Document is current

Article History

Received: 3 May 2024

Accepted: 22 October 2024

First Online: 22 November 2024

Declarations

:

: The study protocol was approved by the Clinical Research Ethics Committee from our institution (HCB/2023/0900). Informed consent was waived due to the retrospective character of data collection and the use of anonymized data.

: Not applicable.

: The authors of this manuscript declare relationships with the following companies: J.R. has served as an advisor to Roche and has received lecture or consultancy fees from AstraZeneca and Roche. A.F. has received lecture fees from Gilead, Boston Scientific, Roche, AstraZeneca and MSD, also advisor fees from AstraZeneca, Roche, SIRTEX, Boston Scientific, AB Exact Science, Taiho and Guerbert. M.R. has served as an advisor and received lecture fees from AstraZeneca, Bayer, BMS, Eli Lilly, Geneos, Ipsen, Merck, Roche, Universal DX, and Engitix Therapeutics. Biotoscana Farma S.A. Travel support by: AstraZeneca, Roche, Bayer, BMS, Lilly. Ipsen Grant Research Support (to the institution): Bayer and Ipsen. Educational Support (to the institution): Bayer, AstraZeneca, BMS, Eisai- Merck MSD, Roche, Ipsen, Lilly, Terumo, Next, Boston Scientific, Ciscar Medical, and Eventy 03 LLC (Egypt). A.D.: has received speaker fees and travel grants from Bayer. The rest of the authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.